[go: up one dir, main page]

ES2036587T3 - Medicamentos para el tratamiento o prevencion del sindrome de abstinencia. - Google Patents

Medicamentos para el tratamiento o prevencion del sindrome de abstinencia.

Info

Publication number
ES2036587T3
ES2036587T3 ES87310290T ES87310290T ES2036587T3 ES 2036587 T3 ES2036587 T3 ES 2036587T3 ES 87310290 T ES87310290 T ES 87310290T ES 87310290 T ES87310290 T ES 87310290T ES 2036587 T3 ES2036587 T3 ES 2036587T3
Authority
ES
Spain
Prior art keywords
prevention
medications
treatment
withdrawal syndrome
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87310290T
Other languages
English (en)
Other versions
ES2036587T5 (es
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27516687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2036587(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB868627909A external-priority patent/GB8627909D0/en
Priority claimed from GB868627881A external-priority patent/GB8627881D0/en
Priority claimed from GB868627883A external-priority patent/GB8627883D0/en
Priority claimed from GB868630083A external-priority patent/GB8630083D0/en
Priority claimed from GB878707177A external-priority patent/GB8707177D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2036587T3 publication Critical patent/ES2036587T3/es
Publication of ES2036587T5 publication Critical patent/ES2036587T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE COMPUESTOS QUE ACTUAN COMO ANTAGONISTAS DE LA 5-HIDROXITRIPTAMINA (5-HT) EN LOS RECEPTORES DE %-HT3 PARA EL ALIVIO O LA PREVENCION DEL SINDROME DE ABSTINENCIA QUE RESULTA DE UNA DROGA O SUSTANCIA EMPLEADA ABUSIVAMENTE Y/O PARA LA SUPRESION DE LA DEPENDENCIA DE DROGAS O SUSTANCIAS EMPLEADAS ABUSIVAMENTE.
ES87310290T 1986-11-21 1987-11-20 Medicamentos para el tratamiento o prevencion del sindrome de abstinencia. Expired - Lifetime ES2036587T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB868627909A GB8627909D0 (en) 1986-11-21 1986-11-21 Medicaments
GB868627881A GB8627881D0 (en) 1986-11-21 1986-11-21 Medicaments
GB868627883A GB8627883D0 (en) 1986-11-21 1986-11-21 Medicaments
GB868630083A GB8630083D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707177A GB8707177D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (2)

Publication Number Publication Date
ES2036587T3 true ES2036587T3 (es) 1995-04-01
ES2036587T5 ES2036587T5 (es) 1995-10-16

Family

ID=27516687

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87310290T Expired - Lifetime ES2036587T5 (es) 1986-11-21 1987-11-20 Medicamentos para el tratamiento o prevencion del sindrome de abstinencia.

Country Status (7)

Country Link
US (2) US4948803A (es)
EP (1) EP0279114B2 (es)
JP (1) JP2765845B2 (es)
DE (1) DE3777805D1 (es)
ES (1) ES2036587T5 (es)
GR (1) GR3004150T3 (es)
WO (1) WO1988003801A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2240476B (en) * 1987-07-11 1992-03-18 Sandoz Ltd 5 ht-3 antagonists for the prevention or reduction of dependence
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
KR920700034A (ko) 1989-04-21 1992-02-19 예안 크라메르·한스 루돌프 하우스 5-ht₃수용체 길항제의 치료용도
IE913621A1 (en) * 1990-10-17 1992-04-22 Beecham Group Plc Novel treatment
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
WO2005037212A2 (en) * 2003-10-14 2005-04-28 Phoenix Pharmalabs, Inc. Treatment of chemical dependency with substantially nonaddicting normorphine and norcodeine derivatives
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP5086091B2 (ja) * 2004-11-05 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
JP5030194B2 (ja) 2004-11-25 2012-09-19 国立大学法人九州大学 薬物依存症治療剤
ATE469897T1 (de) * 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
CN101163701A (zh) * 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
US20110288115A1 (en) 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
DK3201203T3 (da) 2014-09-29 2021-08-23 Takeda Pharmaceuticals Co Krystallinsk form af 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indol-3-carboxamid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
US4499096A (en) * 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
CH664152A5 (fr) * 1984-01-25 1988-02-15 Glaxo Group Ltd Derives de tetrahydrocarbazolones.
CY1908A (en) * 1984-12-20 1985-12-13 Sandoz Ag Treatment of gastrointestinal disorders using 5-HT3 antagonists
DE3689974T2 (de) * 1985-03-14 1994-11-03 Beecham Group Plc Arzneimittel zur Behandlung von Emesis.
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
US4808581A (en) * 1986-03-17 1989-02-28 Glaxo Group Limited Imidazolyl- indolylpropanones as 5-HT3 receptor antagonists
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
PH23937A (en) * 1986-12-16 1990-01-23 Robins Co Inc A H Anxiolytic-n-(1-azabicyclo(2.2.2.)oct-3-yl)benzamides and thiobenzamides
DE3751404T2 (de) * 1986-12-17 1995-12-21 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten

Also Published As

Publication number Publication date
GR3004150T3 (en) 1993-03-31
WO1988003801A1 (en) 1988-06-02
US4948803A (en) 1990-08-14
US5298510A (en) 1994-03-29
EP0279114A1 (en) 1988-08-24
EP0279114B2 (en) 1995-08-23
JP2765845B2 (ja) 1998-06-18
EP0279114B1 (en) 1992-03-25
JPH01502186A (ja) 1989-08-03
ES2036587T5 (es) 1995-10-16
DE3777805D1 (de) 1992-04-30

Similar Documents

Publication Publication Date Title
ES2036587T5 (es) Medicamentos para el tratamiento o prevencion del sindrome de abstinencia.
AR020020A1 (es) Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
UY23992A1 (es) Procedimiento para la preparación de compuestos de 1-fenil-3-dimetilamino-propano
AR004134A1 (es) Derivados 2-amino-6-anilino-purina y procedimiento y nuevos intermediarios para su preparacion, formulaciones farmaceuticas que comprenden talesderivados y el uso de estos derivados como medicamentos.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2072447T3 (es) Locion analgesica externa y procedimiento de preparacion.
KR900004352A (ko) 뇌졸중 치료용 의약
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
AU7023987A (en) Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ES2075129T3 (es) Preparacion de gel que contiene estrogeno.
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
ES2084168T3 (es) Composiciones antimalaricas.
ES2067874T3 (es) Derivados de acetamida.
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
EP0105361A4 (en) ANTAGONISM OF MEDICINAL PRODUCTS OF THE CENTRAL VENEER SYSTEM BY ADMINISTRATING 4-AMINOPYRIDINE ALONE OR IN CONNECTION WITH OTHER MEDICINES.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
SE8703169L (sv) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma
ES2178188T3 (es) Composiciones antitusigenas que contienen teobromina.
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
SV1998000119A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa. ref. lea 32671-sv
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.